Selected Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2024

Table Text Blocks

Selected Quarterly Financial Data (Unaudited)

	First		Second		Third		Fourth		Total
	Quarter		Quarter		Quarter		Quarter		Year
	(in thousands, except per share data)
2024
Total revenues	$	74,877	$	94,396	$	91,592	$	90,545	$	351,410
Total cost and expenses		63,857		69,419		65,956		59,054		258,286
Other income (expense), net		(6,062)		(6,101)		(8,267)		(7,496)		(27,926)
Net income (loss)		(4,162)		(860)		3,646		2,256		880
Comprehensive income (loss)		(2,053)		(408)		2,064		5,231		4,834
Net income (loss) per share—basic (1)		(0.03)		(0.01)		0.02		0.01		0.01
Net income (loss) per share—diluted (1)		(0.03)		(0.01)		0.02		0.01		0.01

(1) The summation of quarterly diluted net income per share does not equate to the calculation for the full fiscal year, as quarterly calculations are performed on a discrete basis.

	First		Second		Third		Fourth		Total
	Quarter		Quarter		Quarter		Quarter		Year
	(in thousands, except per share data)
2023
Total revenues	$	104,061	$	107,382	$	113,739	$	117,553	$	442,735
Total cost and expenses		43,964		1,190,521		73,716		79,964		1,388,165
Other income (expense), net		5,764		6,917		(8,091)		(7,229)		(2,639)
Net income (loss)		45,714		(1,089,478)		13,950		(1,745)		(1,031,559)
Net income (loss) attributable to Ironwood Pharmaceuticals, Inc.		45,714		(1,062,187)		15,321		(1,087)		(1,002,239)
Comprehensive income (loss) attributable to Ironwood Pharmaceuticals, Inc.		45,714		(1,062,187)		14,569		(3,303)		(1,005,207)
Net income per share—basic (1)		0.30		(6.84)		0.10		(0.01)		(6.45)
Net income per share—diluted (1)		0.25		(6.84)		0.09		(0.01)		(6.45)

(1) The summation of quarterly diluted net income per share does not equate to the calculation for the full fiscal year, as quarterly calculations are performed on a discrete basis.